Drug improves metastatic prostate cancer survival

​​​​​​​The first interim results of ENZAMET have been reported by an Australian-led team

Taking enzalutamide improves overall survival and progression-free survival in men with hormone-sensitive metastatic prostate cancer compared with standard antiandrogen therapies, report Australian researchers.